Cell Proliferation and Viability Assay

Enhancing Cellular Viability Analysis for Drug Discovery

At Sygnature Discovery, we have harnessed a diverse array of techniques to help you uncover biologically active compounds that illuminate the effects of target inactivation on cell proliferation, activation, apoptosis, or cytotoxic cell death.

Exploring Cell Proliferation and Viability Analysis

Cell proliferation and viability assays serve as robust tools, playing a pivotal role in the discovery of novel therapeutic agents. Most in vitro proliferation assays not only determine the number of viable cells but also encompass methods for quantifying cell nuclei, assessing metabolic activity, gauging cell redox potential, and evaluating mitochondrial integrity.

These versatile proliferation assays can be seamlessly integrated with cytotoxicity or apoptosis assays, enabling real-time monitoring of cellular responses to compound treatments. Compound-induced cell apoptosis can be quantified through indicators like an increase in cell membrane permeability, the loss of membrane asymmetry, or the activation of caspases.

Our automated liquid handling systems facilitate high-throughput data acquisition, expediting compound validation and aiding selection for subsequent screening cycles within the Design-Make-Test-Analyse framework. These methodologies for assessing cell proliferation and viability find application across both Phenotypic and target-driven drug discovery projects.

Noteworthy applications include:

  • Peripheral blood mononuclear cells (PBMCs) obtained from our Blood Donor Panel
  • Primary cell populations or subpopulations (T cells, B cells, Natural Killer cells, macrophages)

Diverse Techniques for Cellular Proliferation, Viability, and Apoptosis Evaluation

Our arsenal of techniques encompasses a range of methods for quantifying cell proliferation, viability, and apoptosis, including:

  • Detection of cell’s metabolic activity
    • Resazurin reduction
    • ATP luciferase coupled reaction
  • Quantification of cell nuclei or cell confluency
    • Fluorescent labelling of DNA/cell nuclei
    • Acquisition of phase contrast images of cells using IncuCyte® ZOOM
  • Detection of actively dividing cells
  • Cell apoptosis/cytotoxicity
    • Caspase 3/7 activation during cell apoptosis
    • Increase in cell membrane permeability
    • Loss in cell membrane asymmetry by detection of exposed phosphatidylserine on cell surface

Illustrating the Significance of Cellular Viability and Proliferation Analysis

Examples of in vitro assays to measure a cell proliferation assay, viability and apoptosis.

Cell Viability & Proliferation Assay Development

Figure A: Resazurin assay using cells treated with two compounds. Compounds display different potency on proliferation of cells.

Cell Viability & Proliferation Assay Development

Figure B: ATP Luciferase coupled assay. Compounds display different potency on proliferation of wild-type versus knock-out cells.

Cell Viability & Proliferation Assay Development

Figure C: BrdU incorporation assay with PMBCs that were left unstimulated or stimulated with PHA in the presence of selected compound. The compound reduces activation and proliferation of T-cells responding to stimulus.

Cell proliferation and Viability

Figure D: Caspase 3/7 Glo® activities in cells treated with a compound. Data expressed in comparison to CellTiter Glo® to demonstrate correlation between a reduction in cell viability with an increase in caspase 3/7 activation.

Cell Viability & Proliferation Assay Development

Figure E: Real-time cell confluency assessment using the IncuCyte® ZOOM instrument. Data display a time-dependent increase in cell confluency in response to stimulation.

Figure F: Detection of cytotoxicity and apoptosis in cells treated with a compound. Data shows dose-dependent increase in CellTox Green® intracellular accumulation and Annexin V binding in response to compound treatment.

Figure G: Determination of compound effect on cell growth. The graph shows a compound that is cytotoxic (X), anti-proliferative (Y) or cytostatic (Z).

In summary, our comprehensive suite of methodologies empowers refined analyses of cell viability and proliferation, underpinning advances in drug discovery and furthering our understanding of cellular responses to therapeutic interventions.

Latest News

View All

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…

Sygnature Discovery invests £3.75M in Compound Management…

Sygnature Discovery collaborates with Axol Bioscience to…